Diligence memo · auto-generated · as of July 2, 2026
SeqOnce BioSciences, Inc.
SeqOnce BioSciences, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
SeqOnce BioSciences, Inc. operates in Biotechnology, based in PASADENA.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
SeqOnce BioSciences, Inc. has raised $1.9M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.0M on 2018-04-20.
Most recent recorded round closed around 2024-10-14.
Valuation (modeled)modeled
Provath models SeqOnce BioSciences, Inc. at approximately $3.6M (range $635K–$9.0M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.26× the median modeled value of Seed Biotechnology companies in 2022–2024 (207 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 78 months.
Last raise 21 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round was 1.1× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 27% of Biotechnology peers (4293 compared).
Modeled value ranks above 8% of those peers.
Closest niche peers: Mesentech Inc., Marlinspike Therapeutics, Inc., Microbial Machines, Inc., Pearl Diagnostics, Inc., Crossfire Medical Inc.
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.